These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23884781)

  • 1. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
    Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.
    Vitale G; Tagliaferri P; Caraglia M; Rampone E; Ciccarelli A; Bianco AR; Abbruzzese A; Lupoli G
    J Clin Endocrinol Metab; 2000 Mar; 85(3):983-8. PubMed ID: 10720027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
    Díez JJ; Iglesias P
    J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
    Faggiano A; Modica R; Severino R; Camera L; Fonti R; Del Prete M; Chiofalo MG; Aria M; Ferolla P; Vitale G; Pezzullo L; Colao A
    Endocrine; 2018 Oct; 62(1):46-56. PubMed ID: 29572709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study.
    Dicitore A; Cantone MC; Gaudenzi G; Saronni D; Carra S; Borghi MO; Albertelli M; Ferone D; Hofland LJ; Persani L; Vitale G
    Neuroendocrinology; 2021; 111(10):937-950. PubMed ID: 33075795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.
    Zatelli MC; Tagliati F; Taylor JE; Rossi R; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2001 May; 86(5):2161-9. PubMed ID: 11344221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
    Cano JM; Galán R; López R
    Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
    Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
    Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide.
    Lupoli G; Cascone E; Arlotta F; Vitale G; Celentano L; Salvatore M; Lombardi G
    Cancer; 1996 Sep; 78(5):1114-8. PubMed ID: 8780551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
    Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leflunomide suppresses growth in human medullary thyroid cancer cells.
    Alhefdhi A; Burke JF; Redlich A; Kunnimalaiyaan M; Chen H
    J Surg Res; 2013 Nov; 185(1):212-6. PubMed ID: 23816245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
    Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
    J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary thyroid carcinoma and hormones.
    Cohen R; Quidville V; Bihan H
    Ann Med Interne (Paris); 2003 Mar; 154(2):109-16. PubMed ID: 12746649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression.
    Fiebiger WC; Scheithauer W; Traub T; Kurtaran A; Gedlicka C; Kornek GV; Virgolini I; Raderer M
    Scand J Gastroenterol; 2002 Feb; 37(2):222-5. PubMed ID: 11843061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.
    Raderer M; Hejna MH; Muller C; Kornek GV; Kurtaran A; Virgolini I; Fiebieger W; Hamilton G; Scheithauer W
    Int J Oncol; 2000 Jun; 16(6):1197-201. PubMed ID: 10811995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
    Bugalho MJ; Domingues R; Borges A
    Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.